Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.41 · Revenue $20.78M · 5 analysts
Est. EPS $-0.45 · Revenue $22.00M · 4 analysts
Est. EPS $-1.35 · Revenue $96.04M · 7 analysts
Est. EPS $-0.50 · Revenue $24.77M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $46.0M | +4174.5% | +0.8% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-48.9M | +31.9% | -50.9% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +100.0% | 0.0% | +1.6% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -175.8% | +97.7% | -25.5% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -106.4% | +98.4% | -49.7% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $109.7M | +257.6% | +16.2% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +238.7% | +103.7% | +16.9% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 6.2% | +2.0% | -4.4% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 4.73x | -83.0% | +6.1% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $596.2M | +30.6% | -0.5% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -1.10 vs -1.12 | +1.6% | -0.29 vs -0.43 | +31.9% |
| Revenue Surprise | $46.0M vs $38.4M | +19.8% | $26.7M vs $19.2M | +39.1% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Long Daniel D. | officer: SVP, Drug Discovery | Common Stock | A | 3,333 | $2.76 |
| Sep 1, 2026 | Long Daniel D. | officer: SVP, Drug Discovery | Common Stock | D | 3,333 | $37.83 |
| Sep 1, 2026 | Long Daniel D. | officer: SVP, Drug Discovery | Stock Option (Right to Buy) | D | 3,333 | $2.76 |
| Aug 24, 2026 | Patni Rajiv | — | — | — | 0 | — |
| Aug 12, 2026 | Third Rock Ventures V, L.P. | 10 percent owner | Common Stock | A | 147,059 | $50.27 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Jeffrey T. Finer | Co-Founder, Chief Executive Officer & Director | USD 1,041,638 | — | 1967 | Active |
Elizabeth Bhatt | President & Chief Operating Officer | USD 735,000 | Female | 1968 | Active |
Gilbert Labrucherie | Chief Financial Officer | USD 711,727 | Male | 1972 | Active |
Samira Shaikhly | Chief People Officer | USD 536,487 | Female | 1970 | Active |
Mark A. Wilson | Chief Legal Officer | — | Male | 1972 | Active |
Arthur Christopoulos BPHARM | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board | — | — | — | Active |
George Xu | Senior Director of Corporate Development & Portfolio Strategy | — | Male | — | Active |
Richard Hansen | Vice President of Technology | — | Male | — | Active |
Robert J. Lefkowitz | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board | — | — | 1944 | Active |
Patrick Sexton | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board | — | — | — | Active |
Septerna, Inc. (SEPN) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to a loss of $0.56 per share a year ago.
Samira Shaikhly sold 11,798 shares of Common Stock on May 26, 2026, for a transaction value of ~$355,000. The transaction reduced direct Common Stock holdings by 93.7%, leaving 793 shares directly owned post-sale.
15,000 shares were exercised and sold for a total of ~$533,000 on June 22, 2026, at a weighted average price of around $35.51 per share. This transaction impacted 13.46% of Long's direct Common Stock holdings, reducing his position to 96,412 shares.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the first detailed preclinical characterization of SEP-479 has been accepted for an oral presentation at the 2026 Endocrine Society's Annual Meeting (ENDO 2026), taking place June 13-16, 2026, in Chicago. The presentation will highlight the pharmacologic profile of SEP-479, a potent, sel.
Septerna, Inc. (SEPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
